Compounds > ro-28-1675
Page last updated: 2024-11-11

ro-28-1675

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9886086
CHEMBL ID1096435
CHEBI ID95004
SCHEMBL ID2645615
MeSH IDM0452240

Synonyms (33)

Synonym
ro-28-1675
ro-0281675
ro-181675
ro-181675-000
CHEMBL1096435 ,
4dc ,
(2r)-3-cyclopentyl-2-[4-(methylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide
(2r)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-n-thiazol-2-yl-propionamide
(r)-3-cyclopentyl-2-(4-(methylsulfonyl)phenyl)-n-(thiazol-2-yl)propanamide
bdbm50346020
BRD-K21672174-001-01-4
(r)-(-)-3-cyclopentyl-2-(4-methanesulfonyl-phenyl)-n-thiazol-2-yl-propionamide
HY-10595
c18h22n2o3s2
3-cyclopentyl-2(r)-(4-methanesulfonyl-phenyl)-n-thiazol-2-yl-propionamide
NEQSWPCDHDQINX-MRXNPFEDSA-N ,
3-cyclopentyl-2(r)-(4-methanesulfonylphenyl)-n-thiazol-2-yl-propionamide
SCHEMBL2645615
599164-57-5
ro 28-1675
ro 28-0450, (r)-
300353-13-3
AKOS030526774
CHEBI:95004
(2r)-3-cyclopentyl-2-(4-methylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide
(2r)-3-cyclopentyl-2-(4-methylsulfonylphenyl)-n-(2-thiazolyl)propanamide
Q27166765
(2r)-3-cyclopentyl-2-[4-(methanesulfonyl)phenyl]-n-(thiazol-2-yl)propionamide
benzeneacetamide,a-(cyclopentylmethyl)-4-(methylsulfonyl)-n-2-thiazolyl-,(ar)-
(r)-3-cyclopentyl-2-(4-methanesulfonyl-phenyl)-n-thiazol-2-yl-propionamide
MS-26184
E98859
ro-281675

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" When administered to db/db mice, this compound demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent reductions in fed blood glucose levels."( Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.
Ashton, KS; Bartberger, MD; Chen, J; Chmait, S; Cupples, R; Fotsch, C; Galbreath, E; Hale, C; Helmering, J; Hong, FT; Jordan, SR; Kunz, RK; Liu, L; Lloyd, DJ; Michelsen, K; Nishimura, N; Norman, MH; Pennington, LD; Poon, SF; Reid, D; Sivits, G; St Jean, DJ; Stec, MM; Tadesse, S; Tamayo, N; Van, G; Yang, KC; Zhang, J, 2014)		0.4

Bioavailability

ExcerptReferenceRelevance
" In normal Wistar rats, the 2,3-disubstituted acrylamide analog 10 was well absorbed and demonstrated robust glucose lowering effects."( 2,3-Disubstituted acrylamides as potent glucokinase activators.
Corbett, WL; Dvorozniak, M; Grimsby, JS; Grippo, JF; Kester, RF; Lou, J; Marcus, L; Moore, DJ; Racha, JK; Sarabu, R; Sidduri, A; Spence, C, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hexokinase-4Homo sapiens (human)EC50 (µMol)0.59500.09001.26876.3200AID600093; AID739243
Hexokinase-4Homo sapiens (human)Kd0.50000.50000.66500.8300AID760055
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hexokinase-4Homo sapiens (human)Activity0.18350.12700.18230.2400AID516871; AID698011
Glucokinase regulatory proteinHomo sapiens (human)Activity0.24000.24000.24000.2400AID478439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
glucose catabolic processHexokinase-4Homo sapiens (human)
regulation of glycolytic processHexokinase-4Homo sapiens (human)
NADP metabolic processHexokinase-4Homo sapiens (human)
response to glucoseHexokinase-4Homo sapiens (human)
positive regulation of insulin secretionHexokinase-4Homo sapiens (human)
cellular response to insulin stimulusHexokinase-4Homo sapiens (human)
glucose homeostasisHexokinase-4Homo sapiens (human)
regulation of potassium ion transportHexokinase-4Homo sapiens (human)
cellular response to leptin stimulusHexokinase-4Homo sapiens (human)
negative regulation of gluconeogenesisHexokinase-4Homo sapiens (human)
positive regulation of glycogen biosynthetic processHexokinase-4Homo sapiens (human)
regulation of insulin secretionHexokinase-4Homo sapiens (human)
glucose 6-phosphate metabolic processHexokinase-4Homo sapiens (human)
canonical glycolysisHexokinase-4Homo sapiens (human)
calcium ion importHexokinase-4Homo sapiens (human)
glucose metabolic processHexokinase-4Homo sapiens (human)
intracellular glucose homeostasisHexokinase-4Homo sapiens (human)
glycolytic processHexokinase-4Homo sapiens (human)
carbohydrate phosphorylationHexokinase-4Homo sapiens (human)
protein import into nucleusGlucokinase regulatory proteinHomo sapiens (human)
response to glucoseGlucokinase regulatory proteinHomo sapiens (human)
response to fructoseGlucokinase regulatory proteinHomo sapiens (human)
negative regulation of glucokinase activityGlucokinase regulatory proteinHomo sapiens (human)
urate metabolic processGlucokinase regulatory proteinHomo sapiens (human)
triglyceride homeostasisGlucokinase regulatory proteinHomo sapiens (human)
carbohydrate derivative metabolic processGlucokinase regulatory proteinHomo sapiens (human)
glucose homeostasisGlucokinase regulatory proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
glucokinase activityHexokinase-4Homo sapiens (human)
protein bindingHexokinase-4Homo sapiens (human)
ATP bindingHexokinase-4Homo sapiens (human)
glucose bindingHexokinase-4Homo sapiens (human)
glucose sensor activityHexokinase-4Homo sapiens (human)
fructokinase activityHexokinase-4Homo sapiens (human)
mannokinase activityHexokinase-4Homo sapiens (human)
protein bindingGlucokinase regulatory proteinHomo sapiens (human)
kinase inhibitor activityGlucokinase regulatory proteinHomo sapiens (human)
fructose-6-phosphate bindingGlucokinase regulatory proteinHomo sapiens (human)
glucose sensor activityGlucokinase regulatory proteinHomo sapiens (human)
carbohydrate bindingGlucokinase regulatory proteinHomo sapiens (human)
enzyme bindingGlucokinase regulatory proteinHomo sapiens (human)
enzyme inhibitor activityGlucokinase regulatory proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmHexokinase-4Homo sapiens (human)
cytosolHexokinase-4Homo sapiens (human)
mitochondrionHexokinase-4Homo sapiens (human)
cytosolHexokinase-4Homo sapiens (human)
nucleoplasmGlucokinase regulatory proteinHomo sapiens (human)
cytoplasmGlucokinase regulatory proteinHomo sapiens (human)
mitochondrionGlucokinase regulatory proteinHomo sapiens (human)
cytosolGlucokinase regulatory proteinHomo sapiens (human)
nucleoplasmGlucokinase regulatory proteinHomo sapiens (human)
cytosolGlucokinase regulatory proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID698021Drug degradation in cynomolgus monkey liver microsomes assessed as formation of metabolite 7 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478459Tmax in CD rat at 30 mg/kg, po2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID478442Activation of glucokinase at 20 uM measured per mg of protein2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698034Drug degradation in Beagle dog liver microsomes assessed as formation of metabolite 4 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698215Hepatic toxicity in Wistar rat assessed as lipidosis at 100 mg/kg, po qd for 5 days by Oil Red O staining2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698018Drug degradation in cynomolgus monkey liver microsomes assessed as formation of metabolite 4 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478441Activation of glucokinase at 1 uM measured per mg of protein2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698220Drug degradation in Wistar rat liver microsomes assessed as formation of metabolite 2/metabolite 3 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698344Drug degradation in Wistar rat liver microsomes assessed as formation of metabolite 5 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698032Drug degradation in Beagle dog liver microsomes assessed as formation of metabolite 1 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478451Clearance in CD rat at 5 mg/kg, iv2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698190Hepatic toxicity in Wistar rat assessed as lipidosis at 300 mg/kg, po administered as single dose after 5 days by Oil Red O staining2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698221Drug degradation in Wistar rat liver microsomes assessed as formation of metabolite 4 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478450Reduction in glucose AUC in C57BL/6J mouse at 50 mg/kg, po pretreated 30 mins by oral glucose tolerance test relative to control2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID478453AUC (0 to infinity) in CD rat at 5 mg/kg, iv2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698159Drug degradation in human liver microsomes assessed as formation of metabolite 7 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698157Drug degradation in human liver microsomes assessed as formation of metabolite 5 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID617469Activation of human recombinant glucokinase expressed in Escherichia coli coexpressing G6PDH at 10 uM using 20 mM glucose measured as ratio of enzyme activation in treated to untreated control by G6PDH coupled continuous spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.
AID698024Drug degradation in CD1 mouse liver microsomes assessed as formation of metabolite 2/metabolite 3 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID600093Activation of human recombinant glucokinase using 6.5 mM glucose by spectrophotometry2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
AID698025Drug degradation in CD1 mouse liver microsomes assessed as formation of metabolite 1 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID738974Antidiabetic activity in ob/ob mouse assessed as reduction in glucose excursion at 30 mg/kg, po by OGTT2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis and SAR of novel glucokinase activators.
AID698023Drug degradation in human liver microsomes assessed as formation of metabolite 2/metabolite 3 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698033Drug degradation in Beagle dog liver microsomes assessed as formation of metabolite 2/metabolite 3 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478445Activation of glucokinase assessed as increase in Km at 1 uM relative to control2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698011Activation of human recombinant glucokinase assessed as concentration required for 1.5 fold increase in enzymatic activity2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID760054Allosteric activation of recombinant wild-type human pancreatic glucokinase expressed in Escherichia coli K-12 assessed as reduction in lag of transient-state enzyme progress curve at 25 to 100 uM by spectrophotometry in absence of glucose2013ACS medicinal chemistry letters, Sep-05, Volume: 4, Issue:7
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
AID617468Activation of human recombinant glucokinase expressed in Escherichia coli coexpressing G6PDH at 10 uM using 5 mM glucose measured as ratio of enzyme activation in compound treated to Ro-28-1675 by G6PDH coupled continuous spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.
AID600094Activation of human recombinant glucokinase using 6.5 mM glucose by spectrophotometry relative to control2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
AID698154Drug degradation in Beagle dog liver microsomes assessed as formation of metabolite 6 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698022Drug degradation in human liver microsomes assessed as formation of metabolite 1 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698189Hepatic toxicity in Wistar rat assessed as increase in serum triglyceride level at 300 mg/kg, po administered as single dose after 5 days by Oil Red O staining2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478446Activation of glucokinase assessed as increase in Km at 20 uM relative to control2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID478455AUC (0 to infinity) in CD rat at 30 mg/kg, po2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID617470Activation of human recombinant glucokinase expressed in Escherichia coli coexpressing G6PDH at 10 uM using 5 mM glucose measured as ratio of enzyme activation in compound treated to Ro-28-1675 by G6PDH coupled continuous spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.
AID617467Activation of human recombinant glucokinase expressed in Escherichia coli coexpressing G6PDH at 10 uM using 5 mM glucose measured as ratio of enzyme activation in treated to untreated control by G6PDH coupled continuous spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.
AID698013Drug degradation in human liver microsomes assessed as formation of metabolite 2 level at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698209Drug degradation in CD1 mouse liver microsomes assessed as formation of metabolite 4 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478452Volume of distribution at steady state in CD rat at 5 mg/kg, iv2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID478456Cmax in CD rat at 10 mg/kg, po2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID516871Activation of glucokinase assessed as concentration required to 50% increase in enzyme activity2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
2,3-Disubstituted acrylamides as potent glucokinase activators.
AID698031Drug degradation in Wistar rat liver microsomes assessed as formation of metabolite 7 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478457Cmax in CD rat at 30 mg/kg, po2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698017Drug degradation in cynomolgus monkey liver microsomes assessed as formation of metabolite 2/metabolite 3 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698345Drug degradation in Wistar rat liver microsomes assessed as formation of metabolite 6 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698218Drug degradation in CD1 mouse liver microsomes assessed as formation of metabolite 6 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478461Oral bioavailability in CD rat at 30 mg/kg2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698016Drug degradation in cynomolgus monkey liver microsomes assessed as formation of metabolite 1 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID1068857Antidiabetic activity in insulin-resistant db/db mouse assessed as reduction of fed blood glucose level at 50 mg/kg, po measured at 4 to 8 hrs2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.
AID760052Allosteric activation of recombinant wild-type human pancreatic glucokinase expressed in Escherichia coli K-12 assessed as reduction in transition time at 20 uM by spectrophotometry in absence of glucose2013ACS medicinal chemistry letters, Sep-05, Volume: 4, Issue:7
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
AID698156Drug degradation in human liver microsomes assessed as formation of metabolite 4 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698192Antidiabetic activity in Wistar rat assessed as reduction of glucose level at 100 mg/kg, po qd for 5 days measured on day 32012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478444Activation of glucokinase at 20 uM relative to control2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698219Drug degradation in CD1 mouse liver microsomes assessed as formation of metabolite 7 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698196Hepatic toxicity in Wistar rat assessed as periportal hepatocellular microvesicular lipidosis at 300 mg/kg, po administered as single dose after 5 days by hematoxylin and eosin staining2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID760049Allosteric activation of recombinant wild-type human pancreatic glucokinase expressed in Escherichia coli K-12 assessed as increase in glucose kcat by enzyme-kinetic study in presence of 200 mM glucose2013ACS medicinal chemistry letters, Sep-05, Volume: 4, Issue:7
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
AID478449Reduction of glucose-stimulated insulin secretion in C57BL/6J mouse isolated pancreatic islets cells after 3 to 4 days2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698191Antidiabetic activity in Wistar rat assessed as reduction of glucose level at 300 mg/kg, po administered as single dose after 5 days measured on day 32012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478458Tmax in CD rat at 10 mg/kg, po2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID478460Oral bioavailability in CD rat at 10 mg/kg2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID478454AUC (0 to infinity) in CD rat at 10 mg/kg, po2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID739243Activation of glucokinase (unknown origin)2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis and SAR of novel glucokinase activators.
AID698019Drug degradation in cynomolgus monkey liver microsomes assessed as formation of metabolite 5 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID478443Activation of glucokinase assessed as increase in Vmax at 1 uM relative to control2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID760048Allosteric activation of recombinant wild-type human pancreatic glucokinase expressed in Escherichia coli K-12 assessed as increase in glucose Vmax by enzyme-kinetic study in presence of 200 mM glucose2013ACS medicinal chemistry letters, Sep-05, Volume: 4, Issue:7
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
AID698216Drug degradation in Wistar rat liver microsomes assessed as formation of metabolite 1 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698020Drug degradation in cynomolgus monkey liver microsomes assessed as formation of metabolite 6 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID739242Activation of glucokinase (unknown origin) relative to control2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis and SAR of novel glucokinase activators.
AID698217Drug degradation in CD1 mouse liver microsomes assessed as formation of metabolite 5 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698153Drug degradation in Beagle dog liver microsomes assessed as formation of metabolite 5 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID760055Binding affinity to recombinant wild-type human pancreatic glucokinase expressed in Escherichia coli K-12 by isothermal titration calorimetry in presence of 200 mM glucose2013ACS medicinal chemistry letters, Sep-05, Volume: 4, Issue:7
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
AID478439Activity of glucokinase assessed as stimulatory concentration required to increase 1.5 fold enzymatic activity2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
AID698158Drug degradation in human liver microsomes assessed as formation of metabolite 6 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID698155Drug degradation in Beagle dog liver microsomes assessed as formation of metabolite 7 at 20 uM after 30 mins by LCMS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.61 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
piragliatin
piragliatin: glucokinase activator		2.4620
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		02.4720
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.4720
Lipidoses
Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.		02.0710
Alloxan Diabetes
[description not available]		02.0810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0810